{"id":213,"date":"2023-04-13T12:00:43","date_gmt":"2023-04-13T10:00:43","guid":{"rendered":"https:\/\/d36deud6t4mnhi.cloudfront.net\/medias\/communique-de-presse\/"},"modified":"2025-02-13T08:07:01","modified_gmt":"2025-02-13T06:07:01","slug":"communiques-de-presse","status":"publish","type":"page","link":"https:\/\/www.ipsen.com\/fr\/communiques-de-presse\/","title":{"rendered":"Communiqu\u00e9s de presse"},"content":{"rendered":"    <section class=\"sub-page-banner bg-img\" style=\"background-image:url(https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2024\/10\/07095609\/A-b_MEDIA-PR_202407_1920x720pix.jpg)\">\n        <div class=\"container content-sec\" role=\"main\" id=\"main\">\n            <nav aria-label=\"breadcrumb\">\n            <ol class=\"breadcrumb\">\n                <li class=\"breadcrumb-item\"><a href=\"https:\/\/www.ipsen.com\/fr\/\">Accueil<\/a><\/li><li class=\"breadcrumb-item active\"><a class=\"link-pointer-events-none\" href=\"#\" aria-current=\"page\">Communiqu\u00e9s de presse<\/a><\/li><\/ol>\n            <\/nav>            <h1 class=\"visible\">Communiqu\u00e9s de presse<\/h1>\n            <p class=\"visible\">Tous les communiqu\u00e9s de presse d\u2019Ipsen destin\u00e9s aux investisseurs, aux journalistes et aux professionnels des m\u00e9dias. <\/p>\n        <\/div>\n    <\/section>\n\n\n\n<section class=\"media-tabs\">\n      <div class=\"container\">\n        <div class=\"media-tabs-inner\">\n          <ul class=\"media-list-ul\">\n                              <li class=\"media-list-items\">\n                      <a class=\"media-item-link active\" href=\"https:\/\/www.ipsen.com\/fr\/communiques-de-presse\/\" tabindex=\"0\">Communiqu\u00e9s de presse<\/a>\n                  <\/li>\n                              <li class=\"media-list-items\">\n                      <a class=\"media-item-link \" href=\"https:\/\/www.ipsen.com\/fr\/declarations\/\" tabindex=\"0\">D\u00e9clarations M\u00e9dias<\/a>\n                  <\/li>\n                              <li class=\"media-list-items\">\n                      <a class=\"media-item-link \" href=\"https:\/\/www.ipsen.com\/fr\/bibliotheque\/\" tabindex=\"0\">Biblioth\u00e8que M\u00e9dias<\/a>\n                  <\/li>\n                      <\/ul>\n          <div id=\"navTabArrows\">\n              <div class=\"tab-nav-arrows\" id=\"tab-nav-prev\"><\/div>\n              <div class=\"tab-nav-arrows\" id=\"tab-nav-next\"><\/div>\n          <\/div>\n        <\/div>\n      <\/div>\n<\/section>\n\n    <section class=\"slim-card  none\">\n        <div class=\"container\">\n          <div class=\"slim-card-inner\">\n                         <div class=\"slim-standard-section\">\n    <div class=\"slim-standard-section-inner\">\n        <div class=\"row reverse-div\">\n            \n            <div class=\"column-12 col-xl-12 col-md-12 col-sm-12\">\n                <!-- slim-standard carousel -->\n                <div class=\"slim-standard-carousel multiple\">\n                    <div class=\"glider-contain\">\n                                                    <div class=\"slim-standard-content-btn\">\n                                <button aria-label=\"Pr\u00e9c\u00e9dent\" class=\"glider-slim-standard-prev disabled\" aria-disabled=\"true\">\n                                    <span><\/span>\n                                <\/button>\n                                <button aria-label=\"Suivant\" class=\"glider-slim-standard-next\" aria-disabled=\"false\">\n                                    <span><\/span>\n                                <\/button>\n                            <\/div>\n                        \n                        <div class=\"glider-slim-standard\">\n                                                            <div class=\"slim-standard-tab glider-slide left-0\" data-gslide=\"0 active visible\" tab-index=\"0\">\n                                    <div class=\"highligth-row\">\n                                        <a href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-realise-de-solides-resultats-en-2024-grace-a-la-bonne-performance-de-toutes-les-aires-therapeutiques-et-annonce-ses-objectifs-pour-lexercice-2025-3025567\/\"  aria-label=\"Ipsen r\u00e9alise de solides r\u00e9sultats en 2024, gr\u00e2ce \u00e0 la bonne performance de toutes les...\">\n                                            <div class=\"column-1\">\n                                                <div class=\"slim-standard-img\">\n                                                                                                                <a href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-realise-de-solides-resultats-en-2024-grace-a-la-bonne-performance-de-toutes-les-aires-therapeutiques-et-annonce-ses-objectifs-pour-lexercice-2025-3025567\/\" >\n                                                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/06\/28121356\/PR-final-fr.jpg\" aria-label=\"Ipsen r\u00e9alise de solides r\u00e9sultats en 2024, gr\u00e2ce \u00e0 la bonne performance de toutes les...\" title=\"Ipsen r\u00e9alise de solides r\u00e9sultats en 2024, gr\u00e2ce \u00e0 la bonne performance de toutes les...\" >\n                                                            <\/a>\n                                                        \n                                                <\/div>\n                                            <\/div>\n                                        <\/a>\n                                        <a href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-realise-de-solides-resultats-en-2024-grace-a-la-bonne-performance-de-toutes-les-aires-therapeutiques-et-annonce-ses-objectifs-pour-lexercice-2025-3025567\/\"  aria-label=\"Ipsen r\u00e9alise de solides r\u00e9sultats en 2024, gr\u00e2ce \u00e0 la bonne performance de toutes les...\">\n                                            <div class=\"column-2\">\n                                                <div class=\"slim-standard-content\">\n                                                    <div class=\"slim-standard-tab-sec\">\n                                                        <button class=\"btn small-btn grey-bg visible\" style=\"background-color:#06768e;\"> Financier <\/button>\n                                                        <p class=\"date-time dark-grey visible\">  &#8211; 13 f\u00e9vrier 2025 <\/p>\n                                                    <\/div>\n                                                    <div class=\"slim-standard-para-sec\">\n                                                        <p class=\"slim-standard-para primary-blue\">\n                                                            Ipsen r\u00e9alise de solides r\u00e9sultats en 2024, gr\u00e2ce \u00e0 la bonne performance de toutes les&#8230;                                                        <\/p>\n                                                    <\/div>\n                                                <\/div>\n                                            <\/div>\n                                        <\/a>\n\n                                        <\/div>\n                                <\/div>\n                                                        <div class=\"slim-standard-tab glider-slide left-1\" data-gslide=\"1  \" tab-index=\"0\">\n                                    <div class=\"highligth-row\">\n                                        <a href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-et-biomunex-annoncent-un-accord-de-licence-mondial-exclusif-pour-un-activateur-de-cellules-mait-une-nouvelle-classe-therapeutique-en-immuno-oncologie-2990251\/\"  aria-label=\"Ipsen et Biomunex annoncent un accord de licence mondial exclusif pour un activateur de cellules...\">\n                                            <div class=\"column-1\">\n                                                <div class=\"slim-standard-img\">\n                                                                                                                <a href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-et-biomunex-annoncent-un-accord-de-licence-mondial-exclusif-pour-un-activateur-de-cellules-mait-une-nouvelle-classe-therapeutique-en-immuno-oncologie-2990251\/\" >\n                                                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/06\/28121356\/PR-final-fr.jpg\" aria-label=\"Ipsen et Biomunex annoncent un accord de licence mondial exclusif pour un activateur de cellules...\" title=\"Ipsen et Biomunex annoncent un accord de licence mondial exclusif pour un activateur de cellules...\" >\n                                                            <\/a>\n                                                        \n                                                <\/div>\n                                            <\/div>\n                                        <\/a>\n                                        <a href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-et-biomunex-annoncent-un-accord-de-licence-mondial-exclusif-pour-un-activateur-de-cellules-mait-une-nouvelle-classe-therapeutique-en-immuno-oncologie-2990251\/\"  aria-label=\"Ipsen et Biomunex annoncent un accord de licence mondial exclusif pour un activateur de cellules...\">\n                                            <div class=\"column-2\">\n                                                <div class=\"slim-standard-content\">\n                                                    <div class=\"slim-standard-tab-sec\">\n                                                        <button class=\"btn small-btn grey-bg visible\" style=\"background-color:#4e6e9a;\"> Partenariat <\/button>\n                                                        <p class=\"date-time dark-grey visible\">  &#8211; 03 d\u00e9cembre 2024 <\/p>\n                                                    <\/div>\n                                                    <div class=\"slim-standard-para-sec\">\n                                                        <p class=\"slim-standard-para primary-blue\">\n                                                            Ipsen et Biomunex annoncent un accord de licence mondial exclusif pour un activateur de cellules&#8230;                                                        <\/p>\n                                                    <\/div>\n                                                <\/div>\n                                            <\/div>\n                                        <\/a>\n\n                                        <\/div>\n                                <\/div>\n                                                        <div class=\"slim-standard-tab glider-slide left-2\" data-gslide=\"2  \" tab-index=\"0\">\n                                    <div class=\"highligth-row\">\n                                        <a href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/bylvay-odevixibat-montre-une-amelioration-soutenue-en-termes-de-severite-des-demangeaisons-et-de-taux-dacides-biliaires-seriques-chez-les-patients-atteints-de-cifp-et-du-sag-2982434\/\"  aria-label=\"Bylvay\u00ae (od\u00e9vixibat) montre une am\u00e9lioration soutenue en termes de s\u00e9v\u00e9rit\u00e9 des d\u00e9mangeaisons et de taux...\">\n                                            <div class=\"column-1\">\n                                                <div class=\"slim-standard-img\">\n                                                                                                                <a href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/bylvay-odevixibat-montre-une-amelioration-soutenue-en-termes-de-severite-des-demangeaisons-et-de-taux-dacides-biliaires-seriques-chez-les-patients-atteints-de-cifp-et-du-sag-2982434\/\" >\n                                                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/06\/28121356\/PR-final-fr.jpg\" aria-label=\"Bylvay\u00ae (od\u00e9vixibat) montre une am\u00e9lioration soutenue en termes de s\u00e9v\u00e9rit\u00e9 des d\u00e9mangeaisons et de taux...\" title=\"Bylvay\u00ae (od\u00e9vixibat) montre une am\u00e9lioration soutenue en termes de s\u00e9v\u00e9rit\u00e9 des d\u00e9mangeaisons et de taux...\" >\n                                                            <\/a>\n                                                        \n                                                <\/div>\n                                            <\/div>\n                                        <\/a>\n                                        <a href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/bylvay-odevixibat-montre-une-amelioration-soutenue-en-termes-de-severite-des-demangeaisons-et-de-taux-dacides-biliaires-seriques-chez-les-patients-atteints-de-cifp-et-du-sag-2982434\/\"  aria-label=\"Bylvay\u00ae (od\u00e9vixibat) montre une am\u00e9lioration soutenue en termes de s\u00e9v\u00e9rit\u00e9 des d\u00e9mangeaisons et de taux...\">\n                                            <div class=\"column-2\">\n                                                <div class=\"slim-standard-content\">\n                                                    <div class=\"slim-standard-tab-sec\">\n                                                        <button class=\"btn small-btn grey-bg visible\" style=\"background-color:#224a81;\"> Maladies rares <\/button>\n                                                        <p class=\"date-time dark-grey visible\">  &#8211; 18 novembre 2024 <\/p>\n                                                    <\/div>\n                                                    <div class=\"slim-standard-para-sec\">\n                                                        <p class=\"slim-standard-para primary-blue\">\n                                                            Bylvay\u00ae (od\u00e9vixibat) montre une am\u00e9lioration soutenue en termes de s\u00e9v\u00e9rit\u00e9 des d\u00e9mangeaisons et de taux&#8230;                                                        <\/p>\n                                                    <\/div>\n                                                <\/div>\n                                            <\/div>\n                                        <\/a>\n\n                                        <\/div>\n                                <\/div>\n                                                        <div class=\"slim-standard-tab glider-slide left-3\" data-gslide=\"3  \" tab-index=\"0\">\n                                    <div class=\"highligth-row\">\n                                        <a href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/iqirvo-elafibranor-montre-des-donnees-defficacite-et-de-tolerance-sur-une-periode-allant-jusqua-trois-ans-chez-les-patients-atteints-de-cbp-avec-une-amelioration-de-la-fatigu-2982128\/\"  aria-label=\"Iqirvo\u00ae (elafibranor) montre des donn\u00e9es d\u2019efficacit\u00e9 et de tol\u00e9rance sur une p\u00e9riode allant jusqu\u2019\u00e0 trois...\">\n                                            <div class=\"column-1\">\n                                                <div class=\"slim-standard-img\">\n                                                                                                                <a href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/iqirvo-elafibranor-montre-des-donnees-defficacite-et-de-tolerance-sur-une-periode-allant-jusqua-trois-ans-chez-les-patients-atteints-de-cbp-avec-une-amelioration-de-la-fatigu-2982128\/\" >\n                                                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/06\/28121356\/PR-final-fr.jpg\" aria-label=\"Iqirvo\u00ae (elafibranor) montre des donn\u00e9es d\u2019efficacit\u00e9 et de tol\u00e9rance sur une p\u00e9riode allant jusqu\u2019\u00e0 trois...\" title=\"Iqirvo\u00ae (elafibranor) montre des donn\u00e9es d\u2019efficacit\u00e9 et de tol\u00e9rance sur une p\u00e9riode allant jusqu\u2019\u00e0 trois...\" >\n                                                            <\/a>\n                                                        \n                                                <\/div>\n                                            <\/div>\n                                        <\/a>\n                                        <a href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/iqirvo-elafibranor-montre-des-donnees-defficacite-et-de-tolerance-sur-une-periode-allant-jusqua-trois-ans-chez-les-patients-atteints-de-cbp-avec-une-amelioration-de-la-fatigu-2982128\/\"  aria-label=\"Iqirvo\u00ae (elafibranor) montre des donn\u00e9es d\u2019efficacit\u00e9 et de tol\u00e9rance sur une p\u00e9riode allant jusqu\u2019\u00e0 trois...\">\n                                            <div class=\"column-2\">\n                                                <div class=\"slim-standard-content\">\n                                                    <div class=\"slim-standard-tab-sec\">\n                                                        <button class=\"btn small-btn grey-bg visible\" style=\"background-color:#224a81;\"> Maladies rares <\/button>\n                                                        <p class=\"date-time dark-grey visible\">  &#8211; 15 novembre 2024 <\/p>\n                                                    <\/div>\n                                                    <div class=\"slim-standard-para-sec\">\n                                                        <p class=\"slim-standard-para primary-blue\">\n                                                            Iqirvo\u00ae (elafibranor) montre des donn\u00e9es d\u2019efficacit\u00e9 et de tol\u00e9rance sur une p\u00e9riode allant jusqu\u2019\u00e0 trois&#8230;                                                        <\/p>\n                                                    <\/div>\n                                                <\/div>\n                                            <\/div>\n                                        <\/a>\n\n                                        <\/div>\n                                <\/div>\n                                                        <div class=\"slim-standard-tab glider-slide left-4\" data-gslide=\"4  \" tab-index=\"0\">\n                                    <div class=\"highligth-row\">\n                                        <a href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-enregistre-une-forte-dynamique-commerciale-au-cours-des-neuf-premiers-mois-de-lannee-2024-et-revoit-a-la-hausse-ses-previsions-pour-lexercice-en-cours-2967449\/\"  aria-label=\"Ipsen enregistre une forte dynamique commerciale au cours des neuf premiers mois de l&#8217;ann\u00e9e 2024...\">\n                                            <div class=\"column-1\">\n                                                <div class=\"slim-standard-img\">\n                                                                                                                <a href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-enregistre-une-forte-dynamique-commerciale-au-cours-des-neuf-premiers-mois-de-lannee-2024-et-revoit-a-la-hausse-ses-previsions-pour-lexercice-en-cours-2967449\/\" >\n                                                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/06\/28121356\/PR-final-fr.jpg\" aria-label=\"Ipsen enregistre une forte dynamique commerciale au cours des neuf premiers mois de l&#8217;ann\u00e9e 2024...\" title=\"Ipsen enregistre une forte dynamique commerciale au cours des neuf premiers mois de l&#8217;ann\u00e9e 2024...\" >\n                                                            <\/a>\n                                                        \n                                                <\/div>\n                                            <\/div>\n                                        <\/a>\n                                        <a href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-enregistre-une-forte-dynamique-commerciale-au-cours-des-neuf-premiers-mois-de-lannee-2024-et-revoit-a-la-hausse-ses-previsions-pour-lexercice-en-cours-2967449\/\"  aria-label=\"Ipsen enregistre une forte dynamique commerciale au cours des neuf premiers mois de l&#8217;ann\u00e9e 2024...\">\n                                            <div class=\"column-2\">\n                                                <div class=\"slim-standard-content\">\n                                                    <div class=\"slim-standard-tab-sec\">\n                                                        <button class=\"btn small-btn grey-bg visible\" style=\"background-color:#06768e;\"> Financier <\/button>\n                                                        <p class=\"date-time dark-grey visible\">  &#8211; 23 octobre 2024 <\/p>\n                                                    <\/div>\n                                                    <div class=\"slim-standard-para-sec\">\n                                                        <p class=\"slim-standard-para primary-blue\">\n                                                            Ipsen enregistre une forte dynamique commerciale au cours des neuf premiers mois de l&#8217;ann\u00e9e 2024&#8230;                                                        <\/p>\n                                                    <\/div>\n                                                <\/div>\n                                            <\/div>\n                                        <\/a>\n\n                                        <\/div>\n                                <\/div>\n                                                        <div class=\"slim-standard-tab glider-slide left-5\" data-gslide=\"5  \" tab-index=\"0\">\n                                    <div class=\"highligth-row\">\n                                        <a href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/le-medicament-kayfanda-odevixibat-dipsen-est-approuve-dans-lunion-europeenne-pour-le-prurit-cholestatique-lie-au-syndrome-dalagille-une-maladie-hepatique-rare-2951259\/\"  aria-label=\"Le m\u00e9dicament Kayfanda\u00ae (od\u00e9vixibat) d\u2019Ipsen est approuv\u00e9 dans l\u2019Union europ\u00e9enne pour le prurit cholestatique li\u00e9...\">\n                                            <div class=\"column-1\">\n                                                <div class=\"slim-standard-img\">\n                                                                                                                <a href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/le-medicament-kayfanda-odevixibat-dipsen-est-approuve-dans-lunion-europeenne-pour-le-prurit-cholestatique-lie-au-syndrome-dalagille-une-maladie-hepatique-rare-2951259\/\" >\n                                                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2024\/09\/20211630\/PR-final-fr.jpg\" aria-label=\"Le m\u00e9dicament Kayfanda\u00ae (od\u00e9vixibat) d\u2019Ipsen est approuv\u00e9 dans l\u2019Union europ\u00e9enne pour le prurit cholestatique li\u00e9...\" title=\"Le m\u00e9dicament Kayfanda\u00ae (od\u00e9vixibat) d\u2019Ipsen est approuv\u00e9 dans l\u2019Union europ\u00e9enne pour le prurit cholestatique li\u00e9...\" >\n                                                            <\/a>\n                                                        \n                                                <\/div>\n                                            <\/div>\n                                        <\/a>\n                                        <a href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/le-medicament-kayfanda-odevixibat-dipsen-est-approuve-dans-lunion-europeenne-pour-le-prurit-cholestatique-lie-au-syndrome-dalagille-une-maladie-hepatique-rare-2951259\/\"  aria-label=\"Le m\u00e9dicament Kayfanda\u00ae (od\u00e9vixibat) d\u2019Ipsen est approuv\u00e9 dans l\u2019Union europ\u00e9enne pour le prurit cholestatique li\u00e9...\">\n                                            <div class=\"column-2\">\n                                                <div class=\"slim-standard-content\">\n                                                    <div class=\"slim-standard-tab-sec\">\n                                                        <button class=\"btn small-btn grey-bg visible\" style=\"background-color:#224a81;\"> Maladies rares <\/button>\n                                                        <p class=\"date-time dark-grey visible\">  &#8211; 23 septembre 2024 <\/p>\n                                                    <\/div>\n                                                    <div class=\"slim-standard-para-sec\">\n                                                        <p class=\"slim-standard-para primary-blue\">\n                                                            Le m\u00e9dicament Kayfanda\u00ae (od\u00e9vixibat) d\u2019Ipsen est approuv\u00e9 dans l\u2019Union europ\u00e9enne pour le prurit cholestatique li\u00e9&#8230;                                                        <\/p>\n                                                    <\/div>\n                                                <\/div>\n                                            <\/div>\n                                        <\/a>\n\n                                        <\/div>\n                                <\/div>\n                                                        <div class=\"slim-standard-tab glider-slide left-6\" data-gslide=\"6  \" tab-index=\"0\">\n                                    <div class=\"highligth-row\">\n                                        <a href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/le-medicament-iqirvo-elafibranor-dipsen-est-approuve-dans-lunion-europeenne-comme-premier-nouveau-traitement-contre-la-cholangite-biliaire-primitive-depuis-pres-dune-2949674\/\"  aria-label=\"Le m\u00e9dicament Iqirvo\u00ae (\u00e9lafibranor) d\u2019Ipsen est approuv\u00e9 dans l\u2019Union europ\u00e9enne comme premier nouveau traitement contre...\">\n                                            <div class=\"column-1\">\n                                                <div class=\"slim-standard-img\">\n                                                                                                                <a href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/le-medicament-iqirvo-elafibranor-dipsen-est-approuve-dans-lunion-europeenne-comme-premier-nouveau-traitement-contre-la-cholangite-biliaire-primitive-depuis-pres-dune-2949674\/\" >\n                                                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2024\/09\/20211630\/PR-final-fr.jpg\" aria-label=\"Le m\u00e9dicament Iqirvo\u00ae (\u00e9lafibranor) d\u2019Ipsen est approuv\u00e9 dans l\u2019Union europ\u00e9enne comme premier nouveau traitement contre...\" title=\"Le m\u00e9dicament Iqirvo\u00ae (\u00e9lafibranor) d\u2019Ipsen est approuv\u00e9 dans l\u2019Union europ\u00e9enne comme premier nouveau traitement contre...\" >\n                                                            <\/a>\n                                                        \n                                                <\/div>\n                                            <\/div>\n                                        <\/a>\n                                        <a href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/le-medicament-iqirvo-elafibranor-dipsen-est-approuve-dans-lunion-europeenne-comme-premier-nouveau-traitement-contre-la-cholangite-biliaire-primitive-depuis-pres-dune-2949674\/\"  aria-label=\"Le m\u00e9dicament Iqirvo\u00ae (\u00e9lafibranor) d\u2019Ipsen est approuv\u00e9 dans l\u2019Union europ\u00e9enne comme premier nouveau traitement contre...\">\n                                            <div class=\"column-2\">\n                                                <div class=\"slim-standard-content\">\n                                                    <div class=\"slim-standard-tab-sec\">\n                                                        <button class=\"btn small-btn grey-bg visible\" style=\"background-color:#224a81;\"> Maladies rares <\/button>\n                                                        <p class=\"date-time dark-grey visible\">  &#8211; 20 septembre 2024 <\/p>\n                                                    <\/div>\n                                                    <div class=\"slim-standard-para-sec\">\n                                                        <p class=\"slim-standard-para primary-blue\">\n                                                            Le m\u00e9dicament Iqirvo\u00ae (\u00e9lafibranor) d\u2019Ipsen est approuv\u00e9 dans l\u2019Union europ\u00e9enne comme premier nouveau traitement contre&#8230;                                                        <\/p>\n                                                    <\/div>\n                                                <\/div>\n                                            <\/div>\n                                        <\/a>\n\n                                        <\/div>\n                                <\/div>\n                                                        <div class=\"slim-standard-tab glider-slide left-7\" data-gslide=\"7  \" tab-index=\"0\">\n                                    <div class=\"highligth-row\">\n                                        <a href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/le-medicament-iqirvo-dipsen-obtient-lapprobation-de-la-fda-via-une-procedure-acceleree-comme-traitement-ppar-premier-de-sa-classe-therapeutique-pour-la-cholangite-biliaire-prim\/\"  aria-label=\"Le m\u00e9dicament Iqirvo\u00ae d\u2019Ipsen obtient l\u2019approbation de la FDA via une proc\u00e9dure acc\u00e9l\u00e9r\u00e9e comme traitement...\">\n                                            <div class=\"column-1\">\n                                                <div class=\"slim-standard-img\">\n                                                                                                                <a href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/le-medicament-iqirvo-dipsen-obtient-lapprobation-de-la-fda-via-une-procedure-acceleree-comme-traitement-ppar-premier-de-sa-classe-therapeutique-pour-la-cholangite-biliaire-prim\/\" >\n                                                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/06\/28121356\/PR-final-fr.jpg\" aria-label=\"Le m\u00e9dicament Iqirvo\u00ae d\u2019Ipsen obtient l\u2019approbation de la FDA via une proc\u00e9dure acc\u00e9l\u00e9r\u00e9e comme traitement...\" title=\"Le m\u00e9dicament Iqirvo\u00ae d\u2019Ipsen obtient l\u2019approbation de la FDA via une proc\u00e9dure acc\u00e9l\u00e9r\u00e9e comme traitement...\" >\n                                                            <\/a>\n                                                        \n                                                <\/div>\n                                            <\/div>\n                                        <\/a>\n                                        <a href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/le-medicament-iqirvo-dipsen-obtient-lapprobation-de-la-fda-via-une-procedure-acceleree-comme-traitement-ppar-premier-de-sa-classe-therapeutique-pour-la-cholangite-biliaire-prim\/\"  aria-label=\"Le m\u00e9dicament Iqirvo\u00ae d\u2019Ipsen obtient l\u2019approbation de la FDA via une proc\u00e9dure acc\u00e9l\u00e9r\u00e9e comme traitement...\">\n                                            <div class=\"column-2\">\n                                                <div class=\"slim-standard-content\">\n                                                    <div class=\"slim-standard-tab-sec\">\n                                                        <button class=\"btn small-btn grey-bg visible\" style=\"background-color:#224a81;\"> Maladies rares <\/button>\n                                                        <p class=\"date-time dark-grey visible\">  &#8211; 10 juin 2024 <\/p>\n                                                    <\/div>\n                                                    <div class=\"slim-standard-para-sec\">\n                                                        <p class=\"slim-standard-para primary-blue\">\n                                                            Le m\u00e9dicament Iqirvo\u00ae d\u2019Ipsen obtient l\u2019approbation de la FDA via une proc\u00e9dure acc\u00e9l\u00e9r\u00e9e comme traitement&#8230;                                                        <\/p>\n                                                    <\/div>\n                                                <\/div>\n                                            <\/div>\n                                        <\/a>\n\n                                        <\/div>\n                                <\/div>\n                                                <\/div>\n                    <\/div>\n\n                <\/div><!--standard-carousel-over -->\n            <\/div><!--grid-div-over -->\n        <\/div>\n\n        <div class=\"slimcard-btn-sec\">\n                    <\/div>\n\n    <\/div>\n<\/div>\n           <\/div>\n        <\/div>\n    <\/section>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-1 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:75%\">\n<section class=\"media-filter\">\n    <div class=\"container media-filter-inner\">\n                <h2 class=\"media-filter-title charcoal-grey\">Plus de communiqu\u00e9s de presse<\/h2>\n                <div class=\"media-filter-main\" id=\"search-total-div\" data-langaugecode=\"fr\" data-paginationtype=\"visible\" data-loadmore=\"hidden\" data-filtertype=\"pressrelease\" data-posttype=\"press_release\"\n            data-pagination=\"visible\" data-parenttermid=\"[3556,3557,3558,3560,3562,3563,3565,3566]\">\n            <div class=\"row\">\n                <div class=\"column-1 col-xl-12 col-md-12 col-sm-12\">\n                                        <!-- media drop down -->\n                    <div class=\"media-drop-down\">\n                        <p class=\"media-drop-heading\">Filtre<\/p>\n                        <div class=\"media-dropdown-items\">\n                            <div class=\"row\">\n                                                            <div class=\"column-1 col-lg-4 col-md-4 col-sm-12\">\n                                    <div class=\"topic-filter\">\n                                                                                <p>Sujet<\/p>\n                                                                                <div class=\"mutltiselect-dropdown topic-cat-dropdown\">\n                                            <select name=\"langOpt[]\" multiple id=\"topicOpt\">\n                                                                                                <option value=\"3556\">Corporate                                                <\/option>\n                                                                                                <option value=\"3557\">Financier                                                <\/option>\n                                                                                                <option value=\"3558\">Neuroscience                                                <\/option>\n                                                                                                <option value=\"3560\">Oncologie                                                <\/option>\n                                                                                                <option value=\"3562\">Partenariat                                                <\/option>\n                                                                                                <option value=\"3563\">Maladies rares                                                <\/option>\n                                                                                                <option value=\"3565\">Recherche                                                <\/option>\n                                                                                                <option value=\"3566\">Durabilit\u00e9                                                <\/option>\n                                                                                            <\/select>\n                                        <\/div>\n                                    <\/div>\n                                <\/div>\n                                                                                                                                <div class=\"column-2 col-lg-4 col-md-4 col-sm-12\">\n                                    <div class=\"period-filter\">\n                                            <p>P\u00e9riode<\/p>\n                                          <div class=\"mutltiselect-dropdown year-dropdown\">\n                                            <select name=\"langOpt[]\" multiple id=\"periodOpt\">\n                                                                                            <option value=\"2025\">2025                                                                                            <option value=\"2024\">2024                                                                                            <option value=\"2023\">2023                                                                                            <option value=\"2022\">2022                                                                                            <option value=\"2021\">2021                                                                                            <option value=\"2020\">2020                                                                                            <option value=\"2019\">2019                                                                                            <option value=\"2018\">2018                                                                                            <option value=\"2017\">2017                                                                                            <option value=\"2016\">2016                                                                                        <\/select>\n                                        <\/div>\n                                    <\/div>\n                                <\/div>\n                                \n                                                                                                            <div class=\"column-3 col-lg-4 col-md-4 \">\n                                            <div class=\"filterby-filter\">\n                                                <p>Filtrer par<\/p>\n                                                <div class=\"input-filter\">\n                                                    <input type=\"search\" name=\"filter-by\" id=\"filter-by\"\n                                                        placeholder=\"Taper un mot cl\u00e9\">\n                                                <\/div>\n                                                <div class=\"filter-by-dropdown\">\n                                                    <p class=\"recent\">recherche r\u00e9cente<\/p>\n                                                                                                        <ul class=\"filter-by-list\">\n                                                                                                            <\/ul>\n                                                <\/div>\n                                            <\/div>\n                                        <\/div>\n                                                                                                                              <\/div>\n                            <div class=\"reset-btn-div\">\n                                <a href=\"#\" class=\"reset-btn\">R\u00e9initialiser<\/a>\n                            <\/div>\n                        <\/div>\n                    <\/div>\n                                        <!-- sorting section -->\n                    \t\t\t\t\t\t\n        <section class=\"media-filter\">\n            <div class=\"container media-filter-inner\">\n                <div class=\"media-filter-main\" id=\"search-total-div\" data-langaugecode=\"en\" data-paginationtype=\"visible\" data-loadmore=\"hidden\" data-filtertype=\"investor-event\" data-posttype=\"event\" data-pagination=\"visible\" data-parenttermid=\"[492,493,1810,494]\">\n                    <div class=\"row\">\n                        <div class=\"column-1 col-xl-12 col-md-12 col-sm-12\">\n                        <div class=\"sorting-sec\">\n                            <div class=\"row\">\n                                                                    <div class=\"column-1 col-xl-6 col-lg-6 col-sm-12\">\n                                        <div class=\"no-of-item-sec\">\n                                            <p>Afficher: <span id=\"start-value\">1<\/span> &#8211; <span id=\"no-of-search\">05<\/span> de <span id=\"total-count\">206<\/span>\n                                                <\/p>\n                                        <\/div>\n                                    <\/div>\n                                                                <div class=\"column-2 col-xl-6 col-lg-6 col-sm-12\">\n                                                                            <div class=\"sort-input\">\n                                            <div class=\"sort-input-inner\">\n                                            <label for=\"sorting-input\">Afficher<\/label>\n                                                                                            <select name=\"order\" aria-label=\"5\" id=\"show-list\">\n                                                    <option value=\"05\" selected>05<\/option>\n                                                    <option value=\"10\" >10<\/option>\n                                                    <option value=\"20\" >20<\/option>\n                                                    <option value=\"30\" >30<\/option>\n                                                    <option value=\"40\" >40<\/option>\n                                                    <option value=\"50\" >50<\/option>\n                                                <\/select>\n                                            <\/div>\n                                        <\/div>\n\t\t\t\t\t\t\t\t\n                                                                                                                <div class=\"sort-input-ascending\">\n                                            <div class=\"sort-input-ascending-inner\">\n                                                <label for=\"sorting-input-ascend\">Trier par<\/label>\n                                                <select name=\"sorting-input-ascend\" id=\"show-list-as\" class=\"show-list-as\">\n                                                    <option value=\"DESC\" aria-label=\"Descendant\" selected>Descendant<\/option>\n                                                    <option value=\"ASC\" aria-label=\"Ascendant\"  >Ascendant<\/option>                                                    \n                                                <\/select>\n                                            <\/div>\n                                        <\/div>                                        \n                                                                    <\/div>\n                            <\/div>\n                        <\/div>\n                        <\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\n\t\t<\/section>\n                                       \n                    <!-- Search listing include start here-->\n                    <div id=\"search-results\" class=\"story-div\">\n                        <!-- Press Release Listing start here -->\n<div class=\"story-div\" id=\"search-div\">\n\t<div>\n<div class=\"row story-row pr-card\">\n    <div class=\"column-1 col-lg-4 col-md-4 col-sm-12\">\n                        <div class=\"story-img\">\n                                            <a href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-realise-de-solides-resultats-en-2024-grace-a-la-bonne-performance-de-toutes-les-aires-therapeutiques-et-annonce-ses-objectifs-pour-lexercice-2025-3025567\/\"><img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/06\/28121356\/PR-final-fr.jpg\" alt=\"Ipsen r\u00e9alise de solides r\u00e9sultats en 2024, gr\u00e2ce \u00e0 la bonne performance de toutes les aires th\u00e9rapeutiques, et annonce ses objectifs pour l'exercice 2025\" title=\"Ipsen r\u00e9alise de solides r\u00e9sultats en 2024, gr\u00e2ce \u00e0 la bonne performance de toutes les aires th\u00e9rapeutiques, et annonce ses objectifs pour l'exercice 2025\"\/><\/a>\n                                    <\/div>\n            <\/div>\n    <div class=\"column-2 col-lg-8 col-md-8 col-sm-12\">\n        <div class=\"story-post\">\n            <div class=\"story-time-div\">\n                <div class=\"story-info-sec\">\n                    <button class=\"btn tag-btn\" style=\"background-color:#06768e\">\n                        Financier                    <\/button>\n                    <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/wp-content\/themes\/ipsen-main\/dist\/images\/radio.png\"\n                        class=\"radio-img desk-span\" alt=\"Ic\u00f4ne de communiqu\u00e9 de presse\" title=\"Ic\u00f4ne de communiqu\u00e9 de presse\" width=\"auto\">\n                    <span class=\"desk-span\">&nbsp;&#8211;&nbsp;\n                        <span class=\"story-date\">13 f\u00e9vrier 2025                            <!-- <span class=\"story-read-time\">8 \u00a0mn de lecture<\/span> -->\n                        <\/span>\n                        <p class=\"mob-span\">\n                            <span class=\"story-date\">13 f\u00e9vrier 2025<\/span>\n                            <!-- <span class=\"story-read-time\"><\/span> -->\n                        <\/p>\n                <\/div>\n                                <div class=\"download\">\n                    <a href=\"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/3ed1ba5c-7d05-49b0-a6f2-c33aa8555423\" download>\n                        <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/wp-content\/themes\/ipsen-main\/dist\/images\/download.png\" alt=\"T\u00e9l\u00e9charger\" title=\"T\u00e9l\u00e9charger\"\/>\n                    <\/a>\n                <\/div>\n                                            <\/div>\n            <div class=\"story-post-content\">\n                    <a href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-realise-de-solides-resultats-en-2024-grace-a-la-bonne-performance-de-toutes-les-aires-therapeutiques-et-annonce-ses-objectifs-pour-lexercice-2025-3025567\/\">\n                        <h5 class=\"blue-txt\">Ipsen r\u00e9alise de solides r\u00e9sultats en 2024, gr\u00e2ce \u00e0 la bonne performance de toutes les aires th\u00e9rapeutiques, et annonce ses objectifs pour l&#8217;exercice 2025<\/h5>\n                    <\/a>\n                    <p class=\"second-post-para\">PARIS, FRANCE, 13 f\u00e9vrier 2025 &#8211; Ipsen (Euronext : IPN ; ADR : IPSEY), groupe biopharmaceutique mondial de sp\u00e9cialit\u00e9, pr\u00e9sente aujourd\u2019hui ses r\u00e9sultats financiers pour l\u2019exercice et le quatri\u00e8me trimestre 2023.<\/p>\n            <\/div>\n        <\/div>\n    <\/div>\n<\/div>\n<section class=\"card-accordion\">\n    <div class=\"accordion filter-card-accord\">\n        <div class=\"accordion-item shadow-none\">\n            <h2 class=\"accordion-header\" id=\"headingOne\">\n                <button class=\"accordion-button accor-btn collapsed\" type=\"button\" data-bs-toggle=\"collapse\"\n                    data-bs-target=\"#collapseOne-74666\" aria-expanded=\"false\" aria-controls=\"collapseOne\">\n                    <span class=\"link-icon\">\n                        <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/wp-content\/themes\/ipsen-main\/dist\/images\/download-link.png\" alt=\"T\u00e9l\u00e9charger\"  title=\"T\u00e9l\u00e9charger\"\/>\n                    <\/span> 4 documents\/liens connexes<\/button>\n            <\/h2>\n            <div id=\"collapseOne-74666\" class=\"accordion-collapse collapse\" aria-labelledby=\"headingOne\"\n                data-bs-parent=\"#accordionExample\">\n                <div class=\"accordion-body\">\n                                        <p>\n                        <a href=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2025\/02\/13080521\/Ipsen-CP_Annonce-des-resultats-annuels-2024_13022025-2.pdf\"\n                            target=\"_blank\">Annonce des r\u00e9sultats annuels 2024<span class=\"link-res-icon\">\n                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/wp-content\/themes\/ipsen-main\/dist\/images\/pdf.png\" alt=\"T\u00e9l\u00e9charger\"  title=\"T\u00e9l\u00e9charger\"\/>\n                            <\/span>\n                            <span class=\"file-size-info\">\n                                (1.28 MB)\n                            <\/span>\n                        <\/a>\n                    <\/p>\n                    <hr>                     <p>\n                        <a href=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2025\/02\/13084033\/Ipsen-FY-2024-Highlights.pdf\"\n                            target=\"_blank\">FY 2024 &#8211; Highlights<span class=\"link-res-icon\">\n                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/wp-content\/themes\/ipsen-main\/dist\/images\/pdf.png\" alt=\"T\u00e9l\u00e9charger\"  title=\"T\u00e9l\u00e9charger\"\/>\n                            <\/span>\n                            <span class=\"file-size-info\">\n                                (391.26 KB)\n                            <\/span>\n                        <\/a>\n                    <\/p>\n                    <hr>                     <p>\n                        <a href=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2025\/02\/13084030\/FY-2024-Presentation-Deck-vF-12022025.pdf\"\n                            target=\"_blank\">FY 2024 &#8211; Pr\u00e9sentation<span class=\"link-res-icon\">\n                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/wp-content\/themes\/ipsen-main\/dist\/images\/pdf.png\" alt=\"T\u00e9l\u00e9charger\"  title=\"T\u00e9l\u00e9charger\"\/>\n                            <\/span>\n                            <span class=\"file-size-info\">\n                                (1.86 MB)\n                            <\/span>\n                        <\/a>\n                    <\/p>\n                    <hr>                                      <p>\n                                         <a href=\"http:\/\/ipsen.to\/FY-2024\" target=\"_blank\">\n                                             Enregistrement de la conf\u00e9rence t\u00e9l\u00e9phonique destin\u00e9e aux investisseurs et analystes                                                                                                  <span class=\"link-res-icon\">\n                                                         <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/wp-content\/themes\/ipsen-main\/dist\/images\/hyperlink.png\" alt=\"Link\" title=\"Link\"\/>\n                                                     <\/span>\n                                                                                      <\/a>\n                                     <\/p>\n                                          <\/div>\n            <\/div>\n        <\/div>\n    <\/div>\n<\/section>\n\t\t\n<\/div>\n<br>\n\t\t\t<div>\n<div class=\"row story-row pr-card\">\n    <div class=\"column-1 col-lg-4 col-md-4 col-sm-12\">\n                        <div class=\"story-img\">\n                                            <a href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-et-biomunex-annoncent-un-accord-de-licence-mondial-exclusif-pour-un-activateur-de-cellules-mait-une-nouvelle-classe-therapeutique-en-immuno-oncologie-2990251\/\"><img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/06\/28121356\/PR-final-fr.jpg\" alt=\"Ipsen et Biomunex annoncent un accord de licence mondial exclusif pour un activateur de cellules MAIT, une nouvelle classe th\u00e9rapeutique en immuno-oncologie\" title=\"Ipsen et Biomunex annoncent un accord de licence mondial exclusif pour un activateur de cellules MAIT, une nouvelle classe th\u00e9rapeutique en immuno-oncologie\"\/><\/a>\n                                    <\/div>\n            <\/div>\n    <div class=\"column-2 col-lg-8 col-md-8 col-sm-12\">\n        <div class=\"story-post\">\n            <div class=\"story-time-div\">\n                <div class=\"story-info-sec\">\n                    <button class=\"btn tag-btn\" style=\"background-color:#4e6e9a\">\n                        Partenariat                    <\/button>\n                    <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/wp-content\/themes\/ipsen-main\/dist\/images\/radio.png\"\n                        class=\"radio-img desk-span\" alt=\"Ic\u00f4ne de communiqu\u00e9 de presse\" title=\"Ic\u00f4ne de communiqu\u00e9 de presse\" width=\"auto\">\n                    <span class=\"desk-span\">&nbsp;&#8211;&nbsp;\n                        <span class=\"story-date\">03 d\u00e9cembre 2024                            <!-- <span class=\"story-read-time\">8 \u00a0mn de lecture<\/span> -->\n                        <\/span>\n                        <p class=\"mob-span\">\n                            <span class=\"story-date\">03 d\u00e9cembre 2024<\/span>\n                            <!-- <span class=\"story-read-time\"><\/span> -->\n                        <\/p>\n                <\/div>\n                                <div class=\"download\">\n                    <a href=\"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/634412b4-0162-441c-9831-4cd460f4511f\" download>\n                        <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/wp-content\/themes\/ipsen-main\/dist\/images\/download.png\" alt=\"T\u00e9l\u00e9charger\" title=\"T\u00e9l\u00e9charger\"\/>\n                    <\/a>\n                <\/div>\n                                            <\/div>\n            <div class=\"story-post-content\">\n                    <a href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-et-biomunex-annoncent-un-accord-de-licence-mondial-exclusif-pour-un-activateur-de-cellules-mait-une-nouvelle-classe-therapeutique-en-immuno-oncologie-2990251\/\">\n                        <h5 class=\"blue-txt\">Ipsen et Biomunex annoncent un accord de licence mondial exclusif pour un activateur de cellules MAIT, une nouvelle classe th\u00e9rapeutique en immuno-oncologie<\/h5>\n                    <\/a>\n                    <p class=\"second-post-para\">PARIS (FRANCE), le 3\u00a0d\u00e9cembre\u00a02024 \u2013 Ipsen (Euronext\u00a0: IPN\u00a0; ADR\u00a0: IPSEY) et Biomunex\u00a0Pharmaceuticals annoncent aujourd\u2019hui la conclusion d\u2019un accord de licence mondial exclusif pour le programme BMX-502. Le BMX-502 est un anticorps bisp\u00e9cifique qui engage et active un sous-ensemble de cellules&#8230;<\/p>\n            <\/div>\n        <\/div>\n    <\/div>\n<\/div>\n\t\t\n<\/div>\n<br>\n\t\t\t<div>\n<div class=\"row story-row pr-card\">\n    <div class=\"column-1 col-lg-4 col-md-4 col-sm-12\">\n                        <div class=\"story-img\">\n                                            <a href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/bylvay-odevixibat-montre-une-amelioration-soutenue-en-termes-de-severite-des-demangeaisons-et-de-taux-dacides-biliaires-seriques-chez-les-patients-atteints-de-cifp-et-du-sag-2982434\/\"><img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/06\/28121356\/PR-final-fr.jpg\" alt=\"Bylvay\u00ae (od\u00e9vixibat) montre une am\u00e9lioration soutenue en termes de s\u00e9v\u00e9rit\u00e9 des d\u00e9mangeaisons et de taux d\u2019acides biliaires s\u00e9riques chez les patients atteints de CIFP et du SAG\" title=\"Bylvay\u00ae (od\u00e9vixibat) montre une am\u00e9lioration soutenue en termes de s\u00e9v\u00e9rit\u00e9 des d\u00e9mangeaisons et de taux d\u2019acides biliaires s\u00e9riques chez les patients atteints de CIFP et du SAG\"\/><\/a>\n                                    <\/div>\n            <\/div>\n    <div class=\"column-2 col-lg-8 col-md-8 col-sm-12\">\n        <div class=\"story-post\">\n            <div class=\"story-time-div\">\n                <div class=\"story-info-sec\">\n                    <button class=\"btn tag-btn\" style=\"background-color:#224a81\">\n                        Maladies rares                    <\/button>\n                    <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/wp-content\/themes\/ipsen-main\/dist\/images\/radio.png\"\n                        class=\"radio-img desk-span\" alt=\"Ic\u00f4ne de communiqu\u00e9 de presse\" title=\"Ic\u00f4ne de communiqu\u00e9 de presse\" width=\"auto\">\n                    <span class=\"desk-span\">&nbsp;&#8211;&nbsp;\n                        <span class=\"story-date\">18 novembre 2024                            <!-- <span class=\"story-read-time\">18 \u00a0mn de lecture<\/span> -->\n                        <\/span>\n                        <p class=\"mob-span\">\n                            <span class=\"story-date\">18 novembre 2024<\/span>\n                            <!-- <span class=\"story-read-time\"><\/span> -->\n                        <\/p>\n                <\/div>\n                                <div class=\"download\">\n                    <a href=\"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/5091dfea-d121-4ace-8737-6be0fd10affa\" download>\n                        <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/wp-content\/themes\/ipsen-main\/dist\/images\/download.png\" alt=\"T\u00e9l\u00e9charger\" title=\"T\u00e9l\u00e9charger\"\/>\n                    <\/a>\n                <\/div>\n                                            <\/div>\n            <div class=\"story-post-content\">\n                    <a href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/bylvay-odevixibat-montre-une-amelioration-soutenue-en-termes-de-severite-des-demangeaisons-et-de-taux-dacides-biliaires-seriques-chez-les-patients-atteints-de-cifp-et-du-sag-2982434\/\">\n                        <h5 class=\"blue-txt\">Bylvay\u00ae (od\u00e9vixibat) montre une am\u00e9lioration soutenue en termes de s\u00e9v\u00e9rit\u00e9 des d\u00e9mangeaisons et de taux d\u2019acides biliaires s\u00e9riques chez les patients atteints de CIFP et du SAG<\/h5>\n                    <\/a>\n                    <p class=\"second-post-para\">PARIS, FRANCE, le 18 novembre 2024 Ipsen (Euronext : IPN\u00a0; ADR\u00a0: IPSEY) annonce aujourd\u2019hui la pr\u00e9sentation de donn\u00e9es lors du congr\u00e8s de l\u2019American Association for the Study of Liver Diseases (AASLD) \u00e9valuant l\u2019efficacit\u00e9 et le profil de tol\u00e9rance \u00e0 long&#8230;<\/p>\n            <\/div>\n        <\/div>\n    <\/div>\n<\/div>\n\t\t\n<\/div>\n<br>\n\t\t\t<div>\n<div class=\"row story-row pr-card\">\n    <div class=\"column-1 col-lg-4 col-md-4 col-sm-12\">\n                        <div class=\"story-img\">\n                                            <a href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/iqirvo-elafibranor-montre-des-donnees-defficacite-et-de-tolerance-sur-une-periode-allant-jusqua-trois-ans-chez-les-patients-atteints-de-cbp-avec-une-amelioration-de-la-fatigu-2982128\/\"><img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/06\/28121356\/PR-final-fr.jpg\" alt=\"Iqirvo\u00ae (elafibranor) montre des donn\u00e9es d\u2019efficacit\u00e9 et de tol\u00e9rance sur une p\u00e9riode allant jusqu\u2019\u00e0 trois ans chez les patients atteints de CBP avec une am\u00e9lioration de la fatigue et du prurit\" title=\"Iqirvo\u00ae (elafibranor) montre des donn\u00e9es d\u2019efficacit\u00e9 et de tol\u00e9rance sur une p\u00e9riode allant jusqu\u2019\u00e0 trois ans chez les patients atteints de CBP avec une am\u00e9lioration de la fatigue et du prurit\"\/><\/a>\n                                    <\/div>\n            <\/div>\n    <div class=\"column-2 col-lg-8 col-md-8 col-sm-12\">\n        <div class=\"story-post\">\n            <div class=\"story-time-div\">\n                <div class=\"story-info-sec\">\n                    <button class=\"btn tag-btn\" style=\"background-color:#224a81\">\n                        Maladies rares                    <\/button>\n                    <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/wp-content\/themes\/ipsen-main\/dist\/images\/radio.png\"\n                        class=\"radio-img desk-span\" alt=\"Ic\u00f4ne de communiqu\u00e9 de presse\" title=\"Ic\u00f4ne de communiqu\u00e9 de presse\" width=\"auto\">\n                    <span class=\"desk-span\">&nbsp;&#8211;&nbsp;\n                        <span class=\"story-date\">15 novembre 2024                            <!-- <span class=\"story-read-time\">18 \u00a0mn de lecture<\/span> -->\n                        <\/span>\n                        <p class=\"mob-span\">\n                            <span class=\"story-date\">15 novembre 2024<\/span>\n                            <!-- <span class=\"story-read-time\"><\/span> -->\n                        <\/p>\n                <\/div>\n                                <div class=\"download\">\n                    <a href=\"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/459a32d3-5839-4ca5-9bde-dd43aa56b30f\" download>\n                        <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/wp-content\/themes\/ipsen-main\/dist\/images\/download.png\" alt=\"T\u00e9l\u00e9charger\" title=\"T\u00e9l\u00e9charger\"\/>\n                    <\/a>\n                <\/div>\n                                            <\/div>\n            <div class=\"story-post-content\">\n                    <a href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/iqirvo-elafibranor-montre-des-donnees-defficacite-et-de-tolerance-sur-une-periode-allant-jusqua-trois-ans-chez-les-patients-atteints-de-cbp-avec-une-amelioration-de-la-fatigu-2982128\/\">\n                        <h5 class=\"blue-txt\">Iqirvo\u00ae (elafibranor) montre des donn\u00e9es d\u2019efficacit\u00e9 et de tol\u00e9rance sur une p\u00e9riode allant jusqu\u2019\u00e0 trois ans chez les patients atteints de CBP avec une am\u00e9lioration de la fatigue et du prurit<\/h5>\n                    <\/a>\n                    <p class=\"second-post-para\">PARIS, FRANCE, le 15 novembre 2024 Ipsen (Euronext : IPN\u00a0; ADR\u00a0: IPSEY) a annonc\u00e9 aujourd\u2019hui que les derni\u00e8res donn\u00e9es concernant Iqirvo\u00ae (elafibranor 80 mg comprim\u00e9s), issues d\u2019une analyse interm\u00e9diaire de l\u2019\u00e9tude d\u2019extension ouverte en cours de l\u2019essai de Phase III&#8230;<\/p>\n            <\/div>\n        <\/div>\n    <\/div>\n<\/div>\n\t\t\n<\/div>\n<br>\n\t\t\t<div>\n<div class=\"row story-row pr-card\">\n    <div class=\"column-1 col-lg-4 col-md-4 col-sm-12\">\n                        <div class=\"story-img\">\n                                            <a href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-enregistre-une-forte-dynamique-commerciale-au-cours-des-neuf-premiers-mois-de-lannee-2024-et-revoit-a-la-hausse-ses-previsions-pour-lexercice-en-cours-2967449\/\"><img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/06\/28121356\/PR-final-fr.jpg\" alt=\"Ipsen enregistre une forte dynamique commerciale au cours des neuf premiers mois de l'ann\u00e9e 2024 et revoit \u00e0 la hausse ses pr\u00e9visions pour l'exercice en cours\" title=\"Ipsen enregistre une forte dynamique commerciale au cours des neuf premiers mois de l'ann\u00e9e 2024 et revoit \u00e0 la hausse ses pr\u00e9visions pour l'exercice en cours\"\/><\/a>\n                                    <\/div>\n            <\/div>\n    <div class=\"column-2 col-lg-8 col-md-8 col-sm-12\">\n        <div class=\"story-post\">\n            <div class=\"story-time-div\">\n                <div class=\"story-info-sec\">\n                    <button class=\"btn tag-btn\" style=\"background-color:#06768e\">\n                        Financier                    <\/button>\n                    <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/wp-content\/themes\/ipsen-main\/dist\/images\/radio.png\"\n                        class=\"radio-img desk-span\" alt=\"Ic\u00f4ne de communiqu\u00e9 de presse\" title=\"Ic\u00f4ne de communiqu\u00e9 de presse\" width=\"auto\">\n                    <span class=\"desk-span\">&nbsp;&#8211;&nbsp;\n                        <span class=\"story-date\">23 octobre 2024                            <!-- <span class=\"story-read-time\">5 \u00a0mn de lecture<\/span> -->\n                        <\/span>\n                        <p class=\"mob-span\">\n                            <span class=\"story-date\">23 octobre 2024<\/span>\n                            <!-- <span class=\"story-read-time\"><\/span> -->\n                        <\/p>\n                <\/div>\n                                <div class=\"download\">\n                    <a href=\"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/2d5cd4d4-83eb-491d-877b-4c6a3fdd8a85\" download>\n                        <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/wp-content\/themes\/ipsen-main\/dist\/images\/download.png\" alt=\"T\u00e9l\u00e9charger\" title=\"T\u00e9l\u00e9charger\"\/>\n                    <\/a>\n                <\/div>\n                                            <\/div>\n            <div class=\"story-post-content\">\n                    <a href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-enregistre-une-forte-dynamique-commerciale-au-cours-des-neuf-premiers-mois-de-lannee-2024-et-revoit-a-la-hausse-ses-previsions-pour-lexercice-en-cours-2967449\/\">\n                        <h5 class=\"blue-txt\">Ipsen enregistre une forte dynamique commerciale au cours des neuf premiers mois de l&#8217;ann\u00e9e 2024 et revoit \u00e0 la hausse ses pr\u00e9visions pour l&#8217;exercice en cours<\/h5>\n                    <\/a>\n                    <p class=\"second-post-para\">PARIS, FRANCE, 23 octobre 2024 &#8211; Ipsen (Euronext : IPN ; ADR : IPSEY), groupe biopharmaceutique mondial de sp\u00e9cialit\u00e9, pr\u00e9sente aujourd\u2019hui son chiffre d\u2019affaires r\u00e9alis\u00e9 depuis le d\u00e9but de l\u2019exercice et pour le troisi\u00e8me trimestre 2024.<\/p>\n            <\/div>\n        <\/div>\n    <\/div>\n<\/div>\n<section class=\"card-accordion\">\n    <div class=\"accordion filter-card-accord\">\n        <div class=\"accordion-item shadow-none\">\n            <h2 class=\"accordion-header\" id=\"headingOne\">\n                <button class=\"accordion-button accor-btn collapsed\" type=\"button\" data-bs-toggle=\"collapse\"\n                    data-bs-target=\"#collapseOne-69786\" aria-expanded=\"false\" aria-controls=\"collapseOne\">\n                    <span class=\"link-icon\">\n                        <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/wp-content\/themes\/ipsen-main\/dist\/images\/download-link.png\" alt=\"T\u00e9l\u00e9charger\"  title=\"T\u00e9l\u00e9charger\"\/>\n                    <\/span> 3 documents\/liens connexes<\/button>\n            <\/h2>\n            <div id=\"collapseOne-69786\" class=\"accordion-collapse collapse\" aria-labelledby=\"headingOne\"\n                data-bs-parent=\"#accordionExample\">\n                <div class=\"accordion-body\">\n                                        <p>\n                        <a href=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2024\/10\/23065628\/Ventes-au-cours-des-neuf-premiers-mois-de-2024.pdf\"\n                            target=\"_blank\">Ventes au cours des neuf premiers mois de 2024<span class=\"link-res-icon\">\n                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/wp-content\/themes\/ipsen-main\/dist\/images\/pdf.png\" alt=\"T\u00e9l\u00e9charger\"  title=\"T\u00e9l\u00e9charger\"\/>\n                            <\/span>\n                            <span class=\"file-size-info\">\n                                (559.79 KB)\n                            <\/span>\n                        <\/a>\n                    <\/p>\n                    <hr>                     <p>\n                        <a href=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2024\/10\/24164500\/Ipsen-YTD-2024-sales-presentation-1.pdf\"\n                            target=\"_blank\">Pr\u00e9sentation des ventes des neuf premiers mois de 2024<span class=\"link-res-icon\">\n                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/wp-content\/themes\/ipsen-main\/dist\/images\/pdf.png\" alt=\"T\u00e9l\u00e9charger\"  title=\"T\u00e9l\u00e9charger\"\/>\n                            <\/span>\n                            <span class=\"file-size-info\">\n                                (1.25 MB)\n                            <\/span>\n                        <\/a>\n                    <\/p>\n                    <hr>                                      <p>\n                                         <a href=\"http:\/\/ipsen.to\/YTD-2024-sales-update\" target=\"_blank\">\n                                             Webcast replay                                                                                                  <span class=\"link-res-icon\">\n                                                         <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/wp-content\/themes\/ipsen-main\/dist\/images\/hyperlink.png\" alt=\"Link\" title=\"Link\"\/>\n                                                     <\/span>\n                                                                                      <\/a>\n                                     <\/p>\n                                          <\/div>\n            <\/div>\n        <\/div>\n    <\/div>\n<\/section>\n\t\t\n<\/div>\n<br>\n\t\t\t<div class=\"pagination\"><span class='page-numbers current'>1<\/span><a class='page-numbers' onclick='paginationClick(2)'>2<\/a><span class='page-numbers dots'>&#8230;<\/span><a class='page-numbers' onclick='paginationClick(42)'>42<\/a><a class='next page-numbers' onclick='paginationClick(2)'><\/a><\/div><\/div>\n<!-- Press Release Listing Ends here -->\n                        <!-- Search listing include end here-->\n                    <\/div>\n                <\/div>\n            <\/div>\n        <\/div>\n    <\/div>\n<\/section><\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:25%\">\n    <section class=\"side-panel contacts-card\">\n        <div class=\"container\">\n            <div class=\"side-media-contacts\">\n    <div class=\"media-contacts-head visible\">\n        <p>Vos contacts d\u00e9di\u00e9s<\/p>\n    <\/div>\n    <div class=\"media-contacts-list\">\n        <div class=\"main-media-contact-list\">\n                               <ul>\n                        <li>\n                            <p class=\"name-label visible\">Relations m\u00e9dias<\/p>\n                            <p class=\"designation-label\"><\/p>\n                            <p class=\"designation-country visible\"><\/p>\n                        <\/li>\n                        <li class=\"parent-list\">\n                          <ul> \n                            \n                                                            <li>\n                                    <ul class=\"phone-child visible\" >\n                                        <li class=\"phone\"><img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/wp-content\/themes\/ipsen-main\/dist\/images\/phone.png\" alt=\"Num\u00e9ro de t\u00e9l\u00e9phone\" title=\"Num\u00e9ro de t\u00e9l\u00e9phone\"><\/li>\n                                        <li class=\"phone-number\"><a href=\"tel:+33 1 58 33 50 00\" id=\"user_phone\">+33 1 58 33 50 00<\/a><\/li>\n                                        <li class=\"copy-icon\"><img decoding=\"async\" class=\"desktop-view\" data-value=\"+33 1 58 33 50 00\" src=\"https:\/\/www.ipsen.com\/wp-content\/themes\/ipsen-main\/dist\/images\/copied.png\" alt=\"Copier le num\u00e9ro de t\u00e9l\u00e9phone\" title=\"Copier le num\u00e9ro de t\u00e9l\u00e9phone\" ><\/li>\n                                    <\/ul>\n                                <\/li>\n                            \n                              \n\n                                                            <li>\n                                    <ul class=\"email-child visible\">\n                                        <li class=\"email\"><img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/wp-content\/themes\/ipsen-main\/dist\/images\/email.png\" alt=\"Adresse e-mail\" title=\"Adresse e-mail\"><\/li>\n                                        <li class=\"email-id\"><a href=\"mailto:IpsenMediaRelations@ipsen.com\" id=\"user_email\">IpsenMediaRelations@ipsen.com<\/a><\/li>\n                                        <li class=\"copy-icon\"><img decoding=\"async\" class=\"desktop-view\" data-value=\"IpsenMediaRelations@ipsen.com\" src=\"https:\/\/www.ipsen.com\/wp-content\/themes\/ipsen-main\/dist\/images\/copied.png\" alt=\"Copier l'adresse e-mail\" title=\"Copier l'adresse e-mail\"><\/li>\n                                    <\/ul>\n                                <\/li>\n                            \n                                                      <\/ul>          \n                        <\/li>\n                                                    <li class=\"mobile-view\">\n                                <a href=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2024\/08\/30172637\/Media-Relations.vcf\" class=\"mobile-only add-to-contacts\">\n                                    <img decoding=\"async\" class=\"mobile-only add-contacts\" src=\"https:\/\/www.ipsen.com\/wp-content\/themes\/ipsen-main\/dist\/images\/add-to-contacts.png\" title=\"Ajouter aux contacts\" alt=\"Ajouter aux contacts\" >\n                                <\/a>\n                            <\/li>\n                                            <\/ul>\n\n                    <hr class=\"down-divider hidden\"> \n                                 \n        <\/div>\n\n        \n    <\/div>\n<\/div>        <\/div> \n    <\/section>\n\n\n    <section class=\"side-panel quick-links\">\n        <div class=\"container\">\n            <div class=\"quick-link-inner\">\n                <div class=\"quick-link-head visible\">\n                    <p class=\"quicklink-block-title\">Restez inform\u00e9<\/p>\n                <\/div>\n                <div class=\"quick-link-list\">\n                    <ul style=\"border: 1px solid #C4C9CB\">\n                                                        <li>\n                                   <a href=\"https:\/\/www.ipsen.com\/fr\/news-registration-iframe\/\" target=\"\">\n                                        Inscrivez-vous pour recevoir nos derni\u00e8res actualit\u00e9s                                    <\/a>\n                                <\/li>\n                                                <\/ul>\n                <\/div>\n            <\/div>\n        <\/div>\n    <\/section>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-213","page","type-page","status-publish","hentry","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Communiqu\u00e9s de presse Ipsen | Derni\u00e8res actualit\u00e9s et mises \u00e0 jour<\/title>\n<meta name=\"description\" content=\"Tenez-vous au courant des derni\u00e8res actualit\u00e9s et mises \u00e0 jour d\u2019Ipsen. Lisez nos communiqu\u00e9s de presse pour vous informer de nos r\u00e9cents travaux de recherche, partenariats et d\u00e9couvertes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/fr\/communiques-de-presse\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Communiqu\u00e9s de presse Ipsen | Derni\u00e8res actualit\u00e9s et mises \u00e0 jour\" \/>\n<meta property=\"og:description\" content=\"Tenez-vous au courant des derni\u00e8res actualit\u00e9s et mises \u00e0 jour d\u2019Ipsen. Lisez nos communiqu\u00e9s de presse pour vous informer de nos r\u00e9cents travaux de recherche, partenariats et d\u00e9couvertes.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/fr\/communiques-de-presse\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-13T06:07:01+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/communiques-de-presse\/\",\"url\":\"https:\/\/www.ipsen.com\/fr\/communiques-de-presse\/\",\"name\":\"Communiqu\u00e9s de presse Ipsen | Derni\u00e8res actualit\u00e9s et mises \u00e0 jour\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\"},\"datePublished\":\"2023-04-13T10:00:43+00:00\",\"dateModified\":\"2025-02-13T06:07:01+00:00\",\"description\":\"Tenez-vous au courant des derni\u00e8res actualit\u00e9s et mises \u00e0 jour d\u2019Ipsen. Lisez nos communiqu\u00e9s de presse pour vous informer de nos r\u00e9cents travaux de recherche, partenariats et d\u00e9couvertes.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/communiques-de-presse\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/fr\/communiques-de-presse\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/communiques-de-presse\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Communiqu\u00e9s de presse\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Communiqu\u00e9s de presse Ipsen | Derni\u00e8res actualit\u00e9s et mises \u00e0 jour","description":"Tenez-vous au courant des derni\u00e8res actualit\u00e9s et mises \u00e0 jour d\u2019Ipsen. Lisez nos communiqu\u00e9s de presse pour vous informer de nos r\u00e9cents travaux de recherche, partenariats et d\u00e9couvertes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/fr\/communiques-de-presse\/","og_locale":"fr_FR","og_type":"article","og_title":"Communiqu\u00e9s de presse Ipsen | Derni\u00e8res actualit\u00e9s et mises \u00e0 jour","og_description":"Tenez-vous au courant des derni\u00e8res actualit\u00e9s et mises \u00e0 jour d\u2019Ipsen. Lisez nos communiqu\u00e9s de presse pour vous informer de nos r\u00e9cents travaux de recherche, partenariats et d\u00e9couvertes.","og_url":"https:\/\/www.ipsen.com\/fr\/communiques-de-presse\/","og_site_name":"Global","article_modified_time":"2025-02-13T06:07:01+00:00","twitter_card":"summary_large_image","twitter_site":"@ipsengroup","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/fr\/communiques-de-presse\/","url":"https:\/\/www.ipsen.com\/fr\/communiques-de-presse\/","name":"Communiqu\u00e9s de presse Ipsen | Derni\u00e8res actualit\u00e9s et mises \u00e0 jour","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/#website"},"datePublished":"2023-04-13T10:00:43+00:00","dateModified":"2025-02-13T06:07:01+00:00","description":"Tenez-vous au courant des derni\u00e8res actualit\u00e9s et mises \u00e0 jour d\u2019Ipsen. Lisez nos communiqu\u00e9s de presse pour vous informer de nos r\u00e9cents travaux de recherche, partenariats et d\u00e9couvertes.","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/fr\/communiques-de-presse\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/fr\/communiques-de-presse\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/fr\/communiques-de-presse\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Communiqu\u00e9s de presse"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/fr\/#website","url":"https:\/\/www.ipsen.com\/fr\/","name":"Global","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/fr\/#organization","name":"IPSEN","url":"https:\/\/www.ipsen.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]}]}},"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/pages\/213","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/comments?post=213"}],"version-history":[{"count":71,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/pages\/213\/revisions"}],"predecessor-version":[{"id":74676,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/pages\/213\/revisions\/74676"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media?parent=213"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}